NewLink Genetics Corp (NASDAQ:NLNK) shares gapped up prior to trading on Thursday . The stock had previously closed at $1.91, but opened at $1.96. NewLink Genetics shares last traded at $1.90, with a volume of 13,632 shares trading hands.

A number of brokerages have recently commented on NLNK. Zacks Investment Research raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Saturday, August 3rd. ValuEngine raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

The firm has a market cap of $70.11 million, a P/E ratio of -1.32 and a beta of 1.21. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.77 and a current ratio of 12.77. The firm’s fifty day moving average is $1.66 and its 200 day moving average is $1.68.

NewLink Genetics (NASDAQ:NLNK) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.02. The business had revenue of $0.15 million during the quarter. NewLink Genetics had a negative net margin of 6,587.56% and a negative return on equity of 34.44%. As a group, equities research analysts forecast that NewLink Genetics Corp will post -0.03 EPS for the current year.

Several hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in shares of NewLink Genetics during the 2nd quarter worth about $178,000. Paloma Partners Management Co bought a new stake in shares of NewLink Genetics during the 2nd quarter worth about $191,000. Worth Venture Partners LLC boosted its holdings in shares of NewLink Genetics by 32.9% during the 2nd quarter. Worth Venture Partners LLC now owns 326,507 shares of the biotechnology company’s stock worth $483,000 after buying an additional 80,858 shares during the period. Vanguard Group Inc. boosted its holdings in shares of NewLink Genetics by 30.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,412,900 shares of the biotechnology company’s stock worth $2,091,000 after buying an additional 330,510 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of NewLink Genetics by 182.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 20,317 shares of the biotechnology company’s stock worth $30,000 after buying an additional 13,136 shares during the period. 29.24% of the stock is owned by institutional investors and hedge funds.

About NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.

Featured Article: What is the significance of a dead cat bounce?

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.